Conferences - Results from #260

ASCO GU 2023: 318: Positron emission tomography of patients with confirmed prostate cancer using 64Cu-SAR-bisPSMA February 16, 2023

ASCO GU 2023: FORMULA-509: A Multicenter Randomized Trial of Post-Operative Salvage Radiotherapy and 6 Months of GnRH Agonist with or Without Abiraterone Acetate/prednisone and Apalutamide Post-Radical Prostatectomy February 16, 2023

ASCO GU 2023: Patient-Level Data Meta-Analysis of a Multi-Modal Artificial Intelligence Prognostic Biomarker in High-Risk Prostate Cancer: Results from Six NRG/RTOG Phase III Randomized Trials February 16, 2023

ASCO GU 2023: Practice Patterns and Predictors of Treatment Intensification in Patients with Metastatic Castration-Sensitive Prostate Cancer February 16, 2023

ASCO GU 2023: Machine-Learning to Predict Utility of Circulating Tumor DNA (ctDNA) for Somatic Genotyping February 16, 2023

ASCO GU 2023: Cost-Effectiveness Analysis of Seven Treatment Regimens in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): A Public Payer Perspective Using Network Meta-Analysis February 16, 2023

ASCO GU 2023: Circulating Tumor DNA Analysis of IMbassador250: Association of ctDNA Fraction, AR Alterations and Therapy Outcome in mCRPC February 16, 2023

ASCO GU 2023: Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy (TRANSPORT): Individual Patient Data Meta-Analysis from the MARCAP Consortium February 16, 2023

ASCO GU 2023: Association of Intermittent vs Continuous Androgen Deprivation Therapy with Cardiovascular Disease and Endocrine/metabolic Disorders in Patients with Metastatic Prostate Cancer February 16, 2023

ASCO GU 2023: Influence of Molecular Imaging on Patient Selection for Treatment Intensification Prior to Salvage Radiation Therapy for Prostate Cancer: A Post Hoc Analysis of the PROPS Trial February 16, 2023

ASCO GU 2023: Best of the Journals: Prostate Cancer - Medical Oncology February 16, 2023

ASCO GU 2023: Darolutamide plus ADT Versus ADT in Metastatic Hormone-Sensitive Prostate Cancer: Open-Label Single-Arm Study with an External Control Arm (ARASEC) February 16, 2023

ASCO GU 2023: Racial Differences in Survival and Healthcare Resource Utilization Among Medicaid-Insured Adults with Metastatic Castration-Sensitive Prostate Cancer February 16, 2023

ASCO GU 2023: Time Interval Between Radium‑223 Therapy and Lutetium-177–prostate-Specific Membrane Antigen (177Lu-PSMA) Treatment and Outcomes in the RALU Study February 16, 2023

ASCO GU 2023: Initial Results of a Phase 2 Pilot Study of Radium-223 and Radiotherapy in Untreated Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone February 16, 2023

ASCO GU 2023: Activity of Lutetium-177 PSMA (Lu-PSMA) and Determinants of Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Cabazitaxel: The PACAP Study February 16, 2023

ASCO GU 2023: Evaluation of a Novel Transcriptomic Tumor Signature (PROSTest) as Response Biomarker for 177Lu-PSMA Therapy in Advanced Prostate Cancer February 16, 2023

ASCO GU 2023: Best of the Journals: Prostate Cancer - Urologic Oncology February 16, 2023

ASCO GU 2023: Impact of Run-in Treatment with Abiraterone Acetate and Prednisone in the MAGNITUDE Study of Niraparib and AAP in Patients with mCRPC and Homologous Recombination Repair Gene Alterations February 16, 2023

ASCO GU 2023: Efficacy of Systemic Therapy Following [177Lu] Lu-PSMA in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC) February 16, 2023

Page 14 of 507